Get the Stockscreener App
1.15
0.88%
0.01
After Hours:
1.16
0.01
+0.87%
Geron Corp stock is traded at $1.15, with a volume of 8.10M.
It is up +0.88% in the last 24 hours and down -17.86% over the past month.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
See More
Previous Close:
$1.14
Open:
$1.14
24h Volume:
8.10M
Relative Volume:
0.49
Market Cap:
$737.75M
Revenue:
$196.12M
Net Income/Loss:
$-69.59M
P/E Ratio:
-11.03
EPS:
-0.1043
Net Cash Flow:
$-126.13M
1W Performance:
-1.71%
1M Performance:
-17.86%
6M Performance:
-15.44%
1Y Performance:
-26.28%
1-Day Range:
$1.12
$1.1662
1-Week Range:
$1.08
$1.22
52-Week Range:
$1.04
$2.01
Geron Corp Stock (GERN) Company Profile
Name
Geron Corp
Sector
Industry
Phone
(650) 473-7700
Address
919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA
Compare GERN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GERN
Geron Corp
|
1.15 | 737.75M | 196.12M | -69.59M | -126.13M | -0.1043 |
VRTX
Vertex Pharmaceuticals Inc
|
444.93 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.14 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
893.52 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.85 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.87 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Geron Corp Stock (GERN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Sell |
| May-08-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Feb-27-25 | Downgrade | B. Riley Securities | Buy → Neutral |
| Feb-26-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-05-24 | Initiated | H.C. Wainwright | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-09-24 | Initiated | Leerink Partners | Outperform |
| Apr-30-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-29-24 | Initiated | TD Cowen | Buy |
| Mar-15-24 | Reiterated | Needham | Buy |
| Sep-12-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-28-23 | Initiated | Goldman | Neutral |
| Oct-28-22 | Initiated | Wedbush | Outperform |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Nov-02-21 | Initiated | Robert W. Baird | Outperform |
| Feb-18-21 | Resumed | B. Riley Securities | Buy |
| Aug-03-20 | Initiated | Stifel | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Sep-03-19 | Initiated | H.C. Wainwright | Buy |
| Aug-15-19 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-09-19 | Upgrade | Needham | Hold → Buy |
| Jan-31-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Oct-02-18 | Downgrade | B. Riley FBR | Buy → Neutral |
| Jul-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Sep-13-16 | Reiterated | FBR & Co. | Outperform |
| Sep-13-16 | Reiterated | FBR Capital | Outperform |
| Dec-07-15 | Reiterated | Piper Jaffray | Overweight |
| Apr-21-15 | Initiated | Oppenheimer | Outperform |
| Jun-12-14 | Upgrade | MLV & Co | Hold → Buy |
| Mar-12-14 | Downgrade | MLV & Co | Buy → Hold |
| Dec-10-13 | Reiterated | MLV & Co | Buy |
| Dec-10-13 | Upgrade | Needham | Hold → Buy |
| Nov-08-13 | Reiterated | MLV & Co | Buy |
| Oct-16-13 | Initiated | MLV & Co | Buy |
| Aug-30-12 | Initiated | Stifel Nicolaus | Buy |
| Jun-28-12 | Initiated | Needham | Hold |
View All
Geron Corp Stock (GERN) Latest News
GERN Stock Builds Momentum On Strong RYTELO Data - StocksToTrade
Geron Corp stock (US3741631036): Phase 3 data keeps focus on first commercial launch - AD HOC NEWS
Why Did GERN Stock Tumble 10% Pre-Market Today? - Stocktwits
Earnings call transcript: Geron Q1 2026 shows revenue growth, stock rises - Investing.com
Geron Corp stock (US3741631036): Focus on valuation as short interest eases - AD HOC NEWS
GERN Stock Chart | GERON CORP (NASDAQ:GERN) - ChartMill
After Plunging 26.6% in 4 Weeks, Here's Why the Trend Might Reverse for Geron (GERN) - Yahoo Finance
GERN SEC FilingsGeron Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference - Yahoo Finance
Geron plans Goldman Sachs healthcare fireside chat, webcast June 8 - Stock Titan
1GERN.MI Technical Analysis | Trend, Signals & Chart Patterns | GERON CORP (BIT:1GERN) - ChartMill
Geron Shareholders Expand Equity Plan and Elect Directors - The Globe and Mail
Geron (NASDAQ: GERN) adds 4.5M shares to 2018 equity incentive plan - Stock Titan
Geron (NASDAQ: GERN) director awarded 220,000 options at $1.26 strike - Stock Titan
Geron (NASDAQ: GERN) director awarded stock options for 220,000 shares at $1.26 - Stock Titan
Geron (GERN) awards director Susan Molineaux 220,000 stock options - Stock Titan
Geron (GERN) director granted 220,000 stock options at $1.26 - Stock Titan
Geron (GERN) director Dawn Carter Bir awarded 220,000 stock options - Stock Titan
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets - Benzinga
GERN: All proposals passed; clinical and commercial strategies advancing, with key trial data ahead - TradingView
Geron Corporation’s SWOT analysis: biotech stock faces sales headwinds - Investing.com
Geron (GERN) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo! Finance Canada
Geron Corp stock (US3741631036): new stock option grants keep hiring momentum in focus - AD HOC NEWS
Five new Geron hires receive options for 333,750 shares - Stock Titan
Shareholders of Geron Corporation Should Contact The Gross Law F - GuruFocus
GERN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Deep Track (GERN) reports 31.7M shares, 4.95% ownership (May 2026) - Stock Titan
TradingKey - TradingKey
Geron reports Q1 revenue growth and updates on blood cancer drug progress. - Pluang
Geron Corporation Announces Positive Real-World Evidence Study of RYTELO® in Lower-Risk Myelodysplastic Syndromes Ahead of EHA 2026 Presentations - Quiver Quantitative
First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026 - ChartMill
RYTELO study: 37.5% of transfusion-dependent went 8 weeks transfusion-free - Stock Titan
Is Geron (GERN) One of the Best US Stocks Under $5 to Buy? - Insider Monkey
10 Best US Stocks Under $5 to Buy - Insider Monkey
Geron Corporation (NASDAQ:GERN) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Soleus group discloses 41.51M GERN shares (6.5%) — Soleus/Guy Levy - Stock Titan
A Look At Geron (GERN) Valuation After Q1 Results And Reaffirmed 2026 Guidance - Yahoo Finance
Geron Corporation (NASDAQ:GERN) Q1 2026 Earnings Call Transcript - Insider Monkey
Geron Corporation (NASDAQ:GERN): Is Breakeven Near? - Moomoo
Can Geron’s (GERN) Narrowing Losses Reframe Expectations For Its Blood Cancer Earnings Potential? - simplywall.st
Geron (GERN) Q1 2026 Earnings Call Transcript - AOL.com
Geron Corporation Q1 2026 Financial Results: Revenue, Net Loss, and SEC Filing Insights - Minichart
symbol__ Stock Quote Price and Forecast - CNN
Geron Corporation Q1 2026 Earnings Call Summary - Yahoo Finance
Geron: Q1 Earnings Snapshot - theheraldreview.com
[10-Q] GERON CORP Quarterly Earnings Report - Stock Titan
Geron Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Geron (GERN) reports Q1 loss, beats revenue estimates - MSN
Geron Q1 Earnings Call Highlights - Yahoo Finance
Geron Corp. (NASDAQ:GERN) Beats Q1 Estimates as RYTELO Sales Momentum Continues - ChartMill
Geron Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
Geron Corp Stock (GERN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.04%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):